(BMRN) Biomarin Pharmaceutical - Ratings and Ratios

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a global biotechnology company specializing in the development and commercialization of innovative therapies for rare and life-threatening genetic disorders. The company focuses on addressing unmet medical needs in conditions such as lysosomal storage disorders, growth disorders, and metabolic diseases. Its product portfolio includes FDA-approved therapies like VIMIZIM (for MPS IV A), VOXZOGO (for achondroplasia), NAGLAZYME (for MPS VI), and PALYNZIQ (for phenylketonuria). Additionally, the company markets BRINEURA for ceroid lipofuscinosis type 2 (Batten disease) and ALDURAZYME for MPS I, as well as KUVAN, an oral treatment for phenylketonuria. Its pipeline includes investigational therapies like BMN 333 (a longer-acting CNP for growth disorders), BMN 349 (for alpha-1 antitrypsin deficiency), and BMN 351 (for Duchenne muscular dystrophy). The company serves specialty pharmacies, hospitals, and distributors worldwide and has collaborations with partners like Catalyst Pharmaceutical Partners and Ares Trading S.A. BioMarin was founded in 1996 and is headquartered in San Rafael, California.

From a technical perspective, BMRN is currently trading at $61.50, below its 20-day SMA of $63.37 and 50-day SMA of $66.90, indicating near-term weakness. The stocks 200-day SMA of $71.69 suggests a broader downtrend. The Average True Range (ATR) of 2.52 reflects moderate volatility. On the fundamental side, the company has a market cap of $11.35 billion, with a trailing P/E of 26.54 and a forward P/E of 14.68, indicating expectations for future earnings growth. The price-to-book ratio of 1.99 and price-to-sales ratio of 3.98 highlight its valuation relative to book value and revenue. Return on equity stands at 7.54%, reflecting moderate profitability.